Bruker
JP Morgan Healthcare Conference, Day 1: Guardant Health, Exact Sciences, Bruker, 10x Genomics, More
Highlights from the first day included Exact Sciences' profitability forecast, an update on QuidelOrtho's integration, and Guardant Health's "quantum leap forward" with its "smart" liquid biopsy platform.
Bruker Takes Majority Stake in Proteomics Tech Firm Biognosys
With Bruker's investments, Biognosys said that it plans to open a US-based advanced proteomics contract research services lab.
For proteomics firms, 2022 marked a reversal from an earlier boom, but the field pushed into emerging areas like single-cell, single-molecule, and spatial analyses.
Precision Oncology Dx Firm Navignostics Raises CHF 7.5 M in Seed Funding From Bruker, Others
The company is developing a system combining single-cell spatial proteomic data with artificial intelligence analysis to guide therapy selection for cancer patients.
Bruker Posts 5 Percent Rise in Q3 Revenues
Revenues were $638.9 million in Q3, up from $608.9 million in Q3 2021 and beating the consensus Wall Street estimate of $608.2 million.